<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="release of vasoactive neuropeptides from nociceptive sensory nerve terminals, including" exact="calcitonin" post="gene-related peptide (CGRP), substance P (SP), and neurokinin A."/>
 <result pre="new therapeutic strategies for the treatment of migraine, such as" exact="anakinra" post="[ 82]. Anakinra is a recombinant nonglycosylated analogue of"/>
 <result pre="all subtypes of cryopyrin-associated periodic syndrome (CAPS). In nonhuman primates," exact="anakinra" post="has been shown to be able to cross the"/>
 <result pre="43 patients with severe cryopyrin-associated periodic syndromes (CAPS) demonstrated that" exact="anakinra" post="treatment significantly decreased central nervous system inflammation and headaches"/>
 <result pre="S. Walker A. Wiens S. Randomized controlled trial of intravenous" exact="dexamethasone" post="to prevent relapse in acute migraine headache Headache 2008"/>
 <result pre="predicting the response of patients with relapsing-remitting multiple sclerosis to" exact="natalizumab" post="treatment Mol. Med. Rep. 2019 20 678 684 10.3892/mmr.2019.10283"/>
 <result pre="M. et al. Long-term efficacy of the interleukin-1 receptor antagonist" exact="anakinra" post="in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile"/>
</results>
